Chainalysis launches Workflows, a no-code tool automating blockchain data analytics without requiring SQL or Python expertise.

As global freight becomes riskier, more valuable, and increasingly regulated, logistics leaders must adopt a new 2026 playbook built on… Leadership Lens: Fixing the misalignment between supply chain ...

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their ...

Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

Cassandra Forcier has been preparing for the holiday shopping season at Building Blocks Toy store for nearly two decades, stocking up on the "it" toy and ensuring there is plenty of paper for ...

However, the Ole Miss head coach will only be coaching one team next season. Kiffin is expected to reveal his plans for 2026 on Saturday, one day following the "Egg Bowl' between the Rebels and ...

Many regions continue to experience changes in how wealth is distributed across different income groups, as gleaming high-rises across several major cities often overshadow communities where basic ...

Incyte (INCY) has signed an agreement with Prelude Therapeutics (PRLD) for an exclusive option license for Prelude's mutant selective JAK2V617F JH2 inhibitor program to treat a type of rare blood ...